TrialBritish journal of cancer2019

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Ben C Creelan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.